Clinical Trials Browser

Phase 2 × Gallbladder Neoplasms × anlotinib × Clear all

NCT07025174 2025-06-17

SAIB

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Phase 2 Enrolling by invitation

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma